Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 10.30 is 383% above its 5-year average of 2.13, near the high end of its 5-year range (0.02–14.21).
As of the fiscal period ended Tuesday, June 30, 2026. 61.62% above its 12-month average of 6.38.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.30.
CURRENT RATIO
10.30
CURRENT RATIO AVG TTM
6.38
CURRENT RATIO AVG 3Y
2.51
CURRENT RATIO AVG 5Y
2.13
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+61.62%
CURRENT VS 3Y AVG
+310.05%
CURRENT VS 5Y AVG
+383.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.48
median of 687 covered companies
CURRENT VS SECTOR MEDIAN
+196.08%
vs the sector median at left
Market Cap
$4.12M
Current Ratio
0.87
TTM Avg
1.88
3Y Avg
4.97
5Y Avg
8.67
Market Cap
$4.33M
Current Ratio
1.57
TTM Avg
3.49
3Y Avg
6.45
5Y Avg
7.07
Market Cap
$4.40M
Current Ratio
40.30
TTM Avg
26.48
3Y Avg
43.98
5Y Avg
50.08
Market Cap
$4.55M
Current Ratio
2.81
TTM Avg
3.29
3Y Avg
4.75
5Y Avg
4.47
Market Cap
$4.69M
Current Ratio
8.63
TTM Avg
2.65
3Y Avg
2.36
5Y Avg
5.21
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.13M | 10.30 | 6.38 | 2.51 | 2.13 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.12M | 0.87 | 1.88 | 4.97 | 8.67 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.08M | 2.01 | 0.91 | 1.26 | 1.78 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.20M | 1.99 | 1.05 | 3.08 | 3.15 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | 2.08 | 2.77 | 2.83 | 2.68 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.33M | 1.57 | 3.49 | 6.45 | 7.07 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | 40.30 | 26.48 | 43.98 | 50.08 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | 2.81 | 3.29 | 4.75 | 4.47 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | 8.63 | 2.65 | 2.36 | 5.21 |
| Nexalin Technology, Inc. (NXL)vs › | $3.53M | 1.25 | 6.05 | 6.00 | 4.06 |
Current Ratio
10.30
Quick Ratio
10.30
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 10.30 |
| 2026-04-30 | 14.21 |
| 2026-01-31 | 3.25 |
| 2025-10-31 | 1.70 |
| 2025-07-31 | 2.41 |
| 2025-04-30 | 1.41 |
| 2025-01-31 | 3.43 |
| 2024-10-31 | 3.10 |
| 2024-07-31 | 3.11 |
| 2024-04-30 | 2.64 |
| 2024-01-31 | 1.09 |
| 2023-09-30 | 2.01 |
| 2023-06-30 | 3.49 |
| 2023-03-31 | 1.02 |
| 2022-12-31 | 0.16 |
| 2022-09-30 | 0.02 |
| 2022-06-30 | 1.81 |
| 2022-03-31 | 2.27 |
| 2021-12-31 | 3.32 |
| 2021-09-30 | 7.55 |
| 2021-06-30 | 6.82 |
| 2021-03-31 | 5.91 |
| 2020-12-31 | 0.30 |
| 2020-09-30 | 0.92 |
| 2020-06-30 | 1.74 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 4.86 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
